- Home
- MSTR vs SNY Comparison
MSTR vs SNY Comparison
Compare MSTR & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSTR
- SNY
- Stock Information
- Founded
- MSTR 1989
- SNY 1994
- Country
- MSTR United States
- SNY France
- Employees
- MSTR N/A
- SNY N/A
- Industry
- MSTR Computer Software: Prepackaged Software
- SNY Biotechnology: Pharmaceutical Preparations
- Sector
- MSTR Technology
- SNY Health Care
- Exchange
- MSTR Nasdaq
- SNY Nasdaq
- Market Cap
- MSTR 103.9B
- SNY 116.1B
- IPO Year
- MSTR 1998
- SNY N/A
- Fundamental
- Price
- MSTR $335.24
- SNY $49.11
- Analyst Decision
- MSTR Strong Buy
- SNY Buy
- Analyst Count
- MSTR 12
- SNY 4
- Target Price
- MSTR $495.17
- SNY $61.50
- AVG Volume (30 Days)
- MSTR 12.2M
- SNY 3.9M
- Earning Date
- MSTR 10-29-2025
- SNY 10-24-2025
- Dividend Yield
- MSTR N/A
- SNY 3.25%
- EPS Growth
- MSTR N/A
- SNY 118.56
- EPS
- MSTR 18.82
- SNY 8.65
- Revenue
- MSTR $462,322,000.00
- SNY $53,714,621,258.00
- Revenue This Year
- MSTR $1.19
- SNY $1.53
- Revenue Next Year
- MSTR $4.30
- SNY $7.06
- P/E Ratio
- MSTR $17.51
- SNY $5.69
- Revenue Growth
- MSTR N/A
- SNY 15.65
- 52 Week Low
- MSTR $178.00
- SNY $44.62
- 52 Week High
- MSTR $543.00
- SNY $60.12
- Technical
- Relative Strength Index (RSI)
- MSTR 46.86
- SNY 54.77
- Support Level
- MSTR $292.36
- SNY $44.62
- Resistance Level
- MSTR $365.15
- SNY $51.05
- Average True Range (ATR)
- MSTR 15.42
- SNY 0.83
- MACD
- MSTR 3.94
- SNY 0.43
- Stochastic Oscillator
- MSTR 52.19
- SNY 68.73
About MSTR MicroStrategy Incorporated
Strategy Inc is a bitcoin treasury company and a provider of business intelligence services. It is designed to provide investors varying degrees of economic exposure to Bitcoin by offering a range of securities, including equity and fixed-income instruments. The company also provides industry AI-powered enterprise analytics software.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.